Literature DB >> 30762585

Differential immune profiles distinguish the mutational subtypes of gastrointestinal stromal tumor.

Gerardo A Vitiello, Timothy G Bowler, Mengyuan Liu, Benjamin D Medina, Jennifer Q Zhang, Nesteene J Param, Jennifer K Loo, Rachel L Goldfeder, Frederic Chibon, Ferdinand Rossi, Shan Zeng, Ronald P DeMatteo.   

Abstract

Gastrointestinal stromal tumor (GIST) is the most common human sarcoma, frequently characterized by an oncogenic mutation in the KIT or platelet-derived growth factor receptor alpha (PDGFRA) genes. We performed RNA sequencing of 75 human GIST tumors from 75 patients, comprising the largest cohort of GISTs sequenced to date, in order to discover differences in the immune infiltrates of KIT and PDGFRA-mutant GIST. Through bioinformatics, immunohistochemistry, and flow cytometry, we found that PDGFRA-mutant GISTs harbored more immune cells with increased cytolytic activity when compared to KIT-mutant GISTs. PDGFRA-mutant GISTs expressed many chemokines, such as CXCL14, at a significantly higher level when compared to KIT-mutant GISTs and exhibited more diverse driver-derived neoepitope:HLA binding, both of which may contribute to PDGFRA-mutant GIST immunogenicity. Through machine learning, we generated gene expression-based immune profiles capable of differentiating KIT and PDGFRA-mutant GISTs, and also identified additional immune features of high PD-1 and PD-L1 expressing tumors across all GIST mutational subtypes, which may provide insight into immunotherapeutic opportunities and limitations in GIST.

Entities:  

Keywords:  Bioinformatics; Cancer immunotherapy; Immunology; Oncogenes; Oncology

Mesh:

Substances:

Year:  2019        PMID: 30762585      PMCID: PMC6486334          DOI: 10.1172/JCI124108

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  62 in total

Review 1.  The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy.

Authors:  Heikki Joensuu; Ronald P DeMatteo
Journal:  Annu Rev Med       Date:  2011-10-13       Impact factor: 13.739

2.  Immune cells in primary and metastatic gastrointestinal stromal tumors (GIST).

Authors:  Silke Cameron; Marieke Gieselmann; Martina Blaschke; Giuliano Ramadori; Laszlo Füzesi
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

3.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

4.  PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes.

Authors:  Vamsi K Mootha; Cecilia M Lindgren; Karl-Fredrik Eriksson; Aravind Subramanian; Smita Sihag; Joseph Lehar; Pere Puigserver; Emma Carlsson; Martin Ridderstråle; Esa Laurila; Nicholas Houstis; Mark J Daly; Nick Patterson; Jill P Mesirov; Todd R Golub; Pablo Tamayo; Bruce Spiegelman; Eric S Lander; Joel N Hirschhorn; David Altshuler; Leif C Groop
Journal:  Nat Genet       Date:  2003-07       Impact factor: 38.330

5.  FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors.

Authors:  Eileen Shi; Juliann Chmielecki; Chih-Min Tang; Kai Wang; Michael C Heinrich; Guhyun Kang; Christopher L Corless; David Hong; Katherine E Fero; James D Murphy; Paul T Fanta; Siraj M Ali; Martina De Siena; Adam M Burgoyne; Sujana Movva; Lisa Madlensky; Gregory M Heestand; Jonathan C Trent; Razelle Kurzrock; Deborah Morosini; Jeffrey S Ross; Olivier Harismendy; Jason K Sicklick
Journal:  J Transl Med       Date:  2016-12-14       Impact factor: 5.531

6.  PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8+ T-Cell-Driven Antitumor Immunity.

Authors:  Sarah L Buchan; Mohannad Fallatah; Stephen M Thirdborough; Vadim Y Taraban; Anne Rogel; Lawrence J Thomas; Christine A Penfold; Li-Zhen He; Michael A Curran; Tibor Keler; Aymen Al-Shamkhani
Journal:  Clin Cancer Res       Date:  2018-03-07       Impact factor: 12.531

7.  GSVA: gene set variation analysis for microarray and RNA-seq data.

Authors:  Sonja Hänzelmann; Robert Castelo; Justin Guinney
Journal:  BMC Bioinformatics       Date:  2013-01-16       Impact factor: 3.169

8.  KIT oncogene inhibition drives intratumoral macrophage M2 polarization.

Authors:  Michael J Cavnar; Shan Zeng; Teresa S Kim; Eric C Sorenson; Lee M Ocuin; Vinod P Balachandran; Adrian M Seifert; Jonathan B Greer; Rachel Popow; Megan H Crawley; Noah A Cohen; Benjamin L Green; Ferdinand Rossi; Peter Besmer; Cristina R Antonescu; Ronald P DeMatteo
Journal:  J Exp Med       Date:  2013-12-09       Impact factor: 14.307

9.  ETV4 collaborates with Wnt/β-catenin signaling to alter cell cycle activity and promote tumor aggressiveness in gastrointestinal stromal tumor.

Authors:  Shan Zeng; Adrian M Seifert; Jennifer Q Zhang; Teresa S Kim; Timothy G Bowler; Michael J Cavnar; Benjamin D Medina; Gerardo A Vitiello; Ferdinand Rossi; Jennifer K Loo; Nesteene J Param; Ronald P DeMatteo
Journal:  Oncotarget       Date:  2017-12-11

10.  Lack of microsatellite instability in gastrointestinal stromal tumors.

Authors:  Nathália C Campanella; Cristovam Scapulatempo-Neto; Lucas Faria Abrahão-Machado; Antônio Talvane Torres De Oliveira; Gustavo N Berardinelli; Denise Peixoto Guimarães; Rui M Reis
Journal:  Oncol Lett       Date:  2017-09-04       Impact factor: 2.967

View more
  26 in total

1.  KITlow Cells Mediate Imatinib Resistance in Gastrointestinal Stromal Tumor.

Authors:  Sudeep Banerjee; Hyunho Yoon; Stephanie Ting; Chih-Min Tang; Mayra Yebra; Alexander T Wenzel; Huwate Yeerna; Jill P Mesirov; Robert J Wechsler-Reya; Pablo Tamayo; Jason K Sicklick
Journal:  Mol Cancer Ther       Date:  2021-08-10       Impact factor: 6.261

2.  Analysis of clinicopathologic features and gene mutations in gastrointestinal stromal tumor: a series of 58 patients.

Authors:  Hao Cheng; Tian Qiu; Su-Sheng Shi
Journal:  Int J Clin Exp Pathol       Date:  2021-12-15

3.  E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor.

Authors:  Joaquín Arribas; César Serrano; Alfonso García-Valverde; Jordi Rosell; Sergi Sayols; David Gómez-Peregrina; Daniel F Pilco-Janeta; Iván Olivares-Rivas; Enrique de Álava; Joan Maurel; Jordi Rubió-Casadevall; Anna Esteve; Marta Gut; Claudia Valverde; Jordi Barretina; Joan Carles; George D Demetri; Jonathan A Fletcher
Journal:  Oncogene       Date:  2021-10-07       Impact factor: 9.867

4.  Age-dependent genomic characteristics and their impact on immunotherapy in lung adenocarcinoma.

Authors:  Peng Li; Shuyu Che; Yingxue Qi; Ningning Luo; Qiuju Lin; Xiaofeng Zhu; Yunpeng Xuan; Mengmeng Li; Jinlong Li; Minghui Ge; Tingting Sun; Chuang Qi; Yongjie Wang
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-15       Impact factor: 4.322

5.  The microphthalmia-associated transcription factor is involved in gastrointestinal stromal tumor growth.

Authors:  Proaño-Pérez Elizabeth; Serrano-Candelas Eva; García-Valverde Alfonso; Rosell Jordi; Gómez-Peregrina David; Navinés-Ferrer Arnau; Guerrero Mario; Serrano César; Martín Margarita
Journal:  Cancer Gene Ther       Date:  2022-10-14       Impact factor: 5.854

6.  Oncogenic KIT Modulates Type I IFN-Mediated Antitumor Immunity in GIST.

Authors:  Mengyuan Liu; Mark S Etherington; Andrew Hanna; Benjamin D Medina; Gerardo A Vitiello; Timothy G Bowler; Nesteene J Param; Lillian Levin; Ferdinand Rossi; Ronald P DeMatteo
Journal:  Cancer Immunol Res       Date:  2021-03-01       Impact factor: 12.020

7.  HAND1 and BARX1 Act as Transcriptional and Anatomic Determinants of Malignancy in Gastrointestinal Stromal Tumor.

Authors:  Matthew L Hemming; Shannon Coy; Jia-Ren Lin; Jessica L Andersen; Joanna Przybyl; Emanuele Mazzola; Amr H Abdelhamid Ahmed; Matt van de Rijn; Peter K Sorger; Scott A Armstrong; George D Demetri; Sandro Santagata
Journal:  Clin Cancer Res       Date:  2021-01-15       Impact factor: 13.801

8.  Immune-infiltration based signature as a novel prognostic biomarker in gastrointestinal stromal tumour.

Authors:  Zhe-Wei Wei; Jing Wu; Wei-Bin Huang; Jin Li; Xiao-Fang Lu; Yu-Jie Yuan; Wen-Jun Xiong; Xin-Hua Zhang; Wei Wang; Yu-Long He; Chang-Hua Zhang
Journal:  EBioMedicine       Date:  2020-06-20       Impact factor: 8.143

9.  Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) shows gene expression patterns associated to immune checkpoint inhibitors response.

Authors:  Maria A Pantaleo; Giuseppe Tarantino; Claudio Agostinelli; Milena Urbini; Margherita Nannini; Maristella Saponara; Chiara Castelli; Silvia Stacchiotti; Elena Fumagalli; Lidia Gatto; Donatella Santini; Antonio De Leo; Teresa Marafioti; Ayse Akarca; Elena Sabattini; Andrea Pession; Andrea Ardizzoni; Valentina Indio; Annalisa Astolfi
Journal:  Oncoimmunology       Date:  2019-06-04       Impact factor: 8.110

10.  Gene Expression Profiling of PDGFRA Mutant GIST Reveals Immune Signatures as a Specific Fingerprint of D842V Exon 18 Mutation.

Authors:  Valentina Indio; Gloria Ravegnini; Annalisa Astolfi; Milena Urbini; Maristella Saponara; Antonio De Leo; Elisa Gruppioni; Giuseppe Tarantino; Sabrina Angelini; Andrea Pession; Maria Abbondanza Pantaleo; Margherita Nannini
Journal:  Front Immunol       Date:  2020-06-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.